MET and neoplasm: In line with these findings, a reanalysis of a discontinued phase 2 trial revealed that cabozantinib, a multi-kinase inhibitor that targets cMET along with AXL, and VEGFR2, displayed anti-tumor activity with 61% disease control rate and a median PFS of 4.8 months in mUM patients (46).